Mahesan Subramaniam: Japan Brings Mitochondrial Therapy to the Frontline of Cardiology
Mahesan Subramaniam, Co-Founder of United Health Tourism, shared a post on LinkedIn:
“There is a moment in a cardiologist’s career when the tools run out — when the heart muscle has lost too many mitochondria, the tiny power plants that keep cardiac cells contracting rhythmically, and no drug can rebuild what ischemia has destroyed.
Researchers at Keio University School of Medicine in Tokyo have now intervened at precisely that biological level, injecting viable mitochondria harvested from a patient’s own healthy skeletal muscle directly into damaged cardiac tissue during bypass surgery.
The technique, validated in a Phase II clinical trial published in The Lancet (2025), enrolled 47 patients with severe ischemic heart failure unresponsive to maximal medical therapy. Within 72 hours of mitochondrial injection into the infarct border zone, cardiac output measurably improved in 89% of participants.
At six months, left ventricular ejection fraction — the gold standard metric of pumping efficiency — had increased from an average of 24% to 41%, crossing from dangerous territory into functional range.
Crucially, because the mitochondria were autologous (from the patient’s own body), immune rejection was a non-issue.
The biology underpinning this is both ancient and elegant. Mitochondria, which retain their own DNA from their bacterial ancestry, can be isolated, concentrated, and re-injected into energy-starved tissue where they are taken up by host cells through macropinocytosis and membrane fusion.
Once inside, they begin generating ATP within hours, rescuing cells that were in metabolic freefall. This bypasses the central limitation of stem-cell therapy: the weeks required for transplanted cells to differentiate and integrate.
The protocol is now being adapted for non-surgical delivery — an intracoronary catheter approach that could treat patients without open-chest access. If this succeeds, mitochondrial therapy could become a frontline cardiac rescue tool globally.
The deeper implication: we may have been thinking about heart repair at the wrong biological scale all along.
Source:
Keio University School of Medicine, The Lancet, 2025.”
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers